Introduction {#sec1}
============

Alzheimer's disease (AD) is a slowly progressing neurodegenerative disorder that begins with mild memory loss and culminates in severe impairment of executive and cognitive functions. Over the past decade, substantial progress has been made in identifying AD-related molecular and cellular processes, but the molecular mechanisms underlying AD pathogenesis remain largely unknown,[@bib1] and the available pharmacological treatments for AD do not slow or stop the disease.[@bib2] Therefore, further investigation of the mechanisms underlying AD is urgently required to enhance our understanding of the disease and to facilitate the development of effective therapeutic strategies.

Accumulating evidence indicates that noncoding RNAs, particularly microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circRNAs, participate in AD-associated pathophysiology, including the formation and development of β-amyloid (Aβ) plaques and neurofibrillary tangles, synaptic loss, and neuronal death.[@bib3]^,^[@bib4] circRNAs are evolutionarily conserved transcripts featuring covalently linked 5′ and 3′ ends that are derived from pre-mRNA back-splicing.[@bib5] Because circRNAs lack 5′ and 3′ ends, their lifetimes typically range from hours to days or longer, making them considerably more stable than linear coding or noncoding mRNAs.[@bib6] Thus, the biological functions of circRNAs might differ from those of other classes of RNAs, and the stability and specific expression of certain circRNAs have identified these RNAs as optimal candidates for biomarkers of aging and neurodegenerative diseases. circRNAs are enriched in neurons and synaptosomes,[@bib7] and, intriguingly, fly and mouse studies have shown that brain circRNAs are regulated during aging, which strongly indicates potential roles for circRNAs in brain aging and aging-associated neurodegenerative diseases.[@bib8]^,^[@bib9]

A current model on circRNAs posits that these RNAs inhibit the functions of miRNAs by acting as miRNA sponges through the competing endogenous RNA (ceRNA) network.[@bib10] These circRNA-associated ceRNA networks might contribute to several disease processes: Han et al.[@bib11] determined that the circRNA circMTO1 acts as a sponge of miRNA-9 to suppress hepatocellular carcinoma progression. Zheng et al.[@bib12] reported that TTBK2 circRNA promotes glioma malignancy by regulating miR-217. Huang et al.[@bib13] found that the circRNA MYLK competitively binds to miRNA-29a-3p, and this results in increased expression of the target genes *DNMT3B*, *VEGFA*, and *ITGB1*, which are involved in the progression of bladder cancer. Fan et al.[@bib14] summarized the functions of circRNAs and their role as a biomarker in cardiovascular diseases. Moreover, Peng et al.[@bib15] reported that the circular RNA ZNF609 functions as a ceRNA to regulate AKT3 expression by sponging miR-150-5p in Hirschsprung's disease.

CDR1as (also known as CiRS-7: a circular RNA sponge bound to miR-7) and miR-7 are both reported to be associated with nervous system development and disease, and CDR1as dysfunction has been found to upregulate miR-7 expression and potentially lead to the downregulation of AD-related targets, including ubiquitin-protein ligase A.[@bib16], [@bib17], [@bib18] The circRNA derived from *SRY* can act as a natural miRNA sponge and thus inhibit the activity of miR-138,[@bib10] which can affect learning and memory by regulating acyl protein thioesterase 1.[@bib19]^,^[@bib20] These are the only reported examples thus far of circRNAs affecting the brain and the nervous system, but additional RNAs might participate in both normal brain function and nervous system disease.

The aforementioned findings raise the possibility that a favorable strategy for gaining insights into neurodegenerative disorders such as AD would be to comprehensively investigate the functions of circRNA-associated ceRNA networks. Elucidation of the potential link between AD and circRNA-associated ceRNA networks could suggest new strategies for combating this life-threatening disease. For the assessment of new potential treatments for AD, mouse models represent one of the most critical research tools. Thus, in this study, we used deep RNA sequencing (RNA-seq) to examine circRNA-associated ceRNA networks in the brain of APP/PS1 mice (which express APP695swe and PS1-dE9 mutations) and wild-type control mice at the 6- and 9-month-old stages. These time points were selected for the measurements because in this research model, Aβ can be detected in the mice when they are 6 months old, extracellular Aβ deposits in the cortex are apparent by 9 months of age, and synaptic transmission and long-term potentiation are clearly impaired in these mice when they are 9 months old.[@bib21] RNA-seq is widely used to determine the differential gene expression profiles that underlie phenotypic differences,[@bib22]^,^[@bib23] and in this study, RNA-seq was used for the first time to identify circRNA-associated ceRNA networks in the APP/PS1 mouse model of AD ([Figure 1](#fig1){ref-type="fig"}); the data we obtained can serve as a useful resource in efforts to develop new therapeutic targets or novel diagnostics for AD.Figure 1The Workflow of RNA-SeqDetails of the mRNA-seq, miRNA-seq, and circRNA-seq methods are described in [Document S1](#mmc1){ref-type="supplementary-material"}.

Results {#sec2}
=======

Overview of circRNA-Seq Data {#sec2.1}
----------------------------

The sequencing generated 739,349,016 raw reads in total: 177,433,438 and 191,552,170 for wild-type and APP/PS1 6-month-old mice, and 185,516,382 and 184,847,026 for wild-type and APP/PS1 9-month-old mice, respectively. After poly(N)-containing, low-quality, and adaptor-containing reads were removed from the raw data, 724,361,150 clean reads remained: 173,777,328 and 186,369,844 for wild-type and APP/PS1 6-month-old mice, and 181,497,660 and 182,716,318 for wild-type and APP/PS1 9-month-old mice. The reference genome and gene model annotation files were downloaded from the genome website directly ([ftp://ftp.ensembl.org/pub/release-93/fasta/mus_musculus/dna/](http://ftp://ftp.ensembl.org/pub/release-93/fasta/mus_musculus/dna/){#interref0010}). An index of the reference genome was built using bowtie2 v.2.2.8, and paired-end clean reads were aligned to the reference genome by using Bowtie.[@bib24] circRNAs were detected and identified using find_circ[@bib6] and CIRI2,[@bib25] and this yielded 15,713 circRNAs, which were used for subsequent analyses.

Overview of miRNA-Seq Data {#sec2.2}
--------------------------

Here, 99,137,837 raw reads were generated in total: 28,672,205 and 20,760,197 for wild-type and APP/PS1 6-month-old mice, and 23,016,993 and 26,688,442 for wild-type and APP/PS1 9-month-old mice. After removal of low-quality and adaptor sequences, 96,028,757 clean reads were obtained: 27,710,151 and 20,281,596 for wild-type and APP/PS1 6-month-old mice, and 22,393,001 and 25,644,009 for wild-type and APP/PS1 9-month-old mice. We filtered these results based on length (18--35 nt), and most selected reads were 22 nt in length in both groups. The selected reads were next mapped to the mouse reference sequence by using Bowtie,[@bib24] and the mapping rates were 94.61% and 94.78% for APP/PS1 and wild-type mice, respectively. These mapped tags were annotated and classified based on alignment with noncoding small RNAs (rRNA, tRNA, small nuclear RNA \[snRNA\], and small nucleolar RNA \[snoRNA\]) in GenBank, repeat-associated RNA, exon- and intron-associated RNAs, and miRBase v.20.0, and we integrated miREvo[@bib26] and miRDeep2[@bib27] software to predict previously unidentified miRNAs. Ultimately, 1,411 mature miRNAs (1,312 known, 99 previously unknown) were detected, and these were used for subsequent analyses.

Overview of mRNA-Seq Data {#sec2.3}
-------------------------

A total of 1,145,853,722 raw reads were generated: 317,603,558 and 276,260,804 for wild-type and APP/PS1 6-month-old mice, and 286,203,120 and 265,786,240 for wild-type and APP/PS1 9-month-old mice. After discarding the reads including adapters, poly(N) \> 10%, and any other potential contaminants, 1,119,187,680 clean reads were obtained: 311,741,312 and 266,033,410 for wild-type and APP/PS1 6-month-old mice, and 278,938,832 and 262,474,126 for wild-type and APP/PS1 9-month-old mice. Reference genome and gene model annotation files were downloaded directly from the genome website ([ftp://ftp.ensembl.org/pub/release-93/fasta/mus_musculus/dna/](http://ftp://ftp.ensembl.org/pub/release-93/fasta/mus_musculus/dna/){#interref0015}). An index of the reference genome was built using bowtie2 v.2.2.8, and paired-end clean reads were aligned to the reference genome by using HISAT2 v.2.0.4.[@bib28] HISAT2 was run with "--rna-strandness RF," other parameters were set as default, and the mapping rates were 91.53% and 91.74% for APP/PS1 and wild-type mice, respectively. We filtered out transcripts that were predicted to hold coding potential by the either/all function of CNCI (Coding-Non-Coding-Index) (v.2),[@bib29] CPC (Coding Potential Calculator) (0.9-r2),[@bib30] PfamScan (v.1.3),[@bib31] and PhyloCSF (phylogenetic codon substitution frequency) (v.20121028),[@bib32] and among these transcripts, 48,718 protein-coding transcripts were identified; these mRNAs were used for subsequent analyses.

Differential Expression Analysis: APP/PS1 versus Wild-Type {#sec2.4}
----------------------------------------------------------

We identified 343 significantly dysregulated circRNA transcripts between the two groups at 6 months ([Figure 2](#fig2){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}); 192 and 151 transcripts were upregulated and downregulated in APP/PS1 mice relative to their levels in wild-type mice, respectively. Moreover, at 9 months, 243 circRNA transcripts were significantly dysregulated: 141 and 102 transcripts were upregulated and downregulated in APP/PS1 mice relative to wild-type ([Figure 2](#fig2){ref-type="fig"}B; [Table S2](#mmc3){ref-type="supplementary-material"}). Cluster analysis of the circRNAs expression was conducted, and a heatmap was constructed to visualize the results ([Figure 2](#fig2){ref-type="fig"}C). Next, based on transcripts per million (TPM) values, 36 significantly dysregulated miRNAs were identified between the two groups at 6 months: 12 miRNAs were upregulated and 24 were downregulated in APP/PS1 mice ([Figure 2](#fig2){ref-type="fig"}D; [Table S3](#mmc4){ref-type="supplementary-material"}); at 9 months, 56 miRNAs were significantly dysregulated: 27 and 29 miRNAs were respectively upregulated and downregulated in APP/PSI mice ([Figure 2](#fig2){ref-type="fig"}E; [Table S4](#mmc5){ref-type="supplementary-material"}). Cluster analysis of miRNA expression was performed, and a heatmap was generated ([Figure 2](#fig2){ref-type="fig"}F). Lastly, we used the value FPKMs (fragments per kilobase of exons per million fragments mapped) to estimate the expression levels of mRNA transcripts. At 6 months, 1,770 mRNA transcripts were significantly dysregulated, with 824 and 946 being respectively upregulated and downregulated in APP/PS1 mice ([Figure 2](#fig2){ref-type="fig"}G; [Table S5](#mmc6){ref-type="supplementary-material"}); at 9 months, 1,678 mRNAs were significantly dysregulated, with 832 and 846 being upregulated and downregulated in APP/PS1 mice ([Figure 2](#fig2){ref-type="fig"}H; [Table S6](#mmc7){ref-type="supplementary-material"}). Once again, cluster analysis was performed on the mRNA expression, and a heatmap was generated ([Figure 2](#fig2){ref-type="fig"}I).Figure 2Expression Profiles of Distinct RNAs(A--C) Expression profiles of circRNAs. (A and B) In the volcano plots, purple, green, and black points represent circRNAs that were downregulated, upregulated, and not significantly different in APP/PS1 mice relative to wild-type control mice at 6 and 9 months, respectively. x axis: log2 ratio of circRNA expression levels between AD and wild-type. y axis: false discovery rate values (−log10 transformed) of circRNAs. (C) Cluster analysis of expression of circRNAs. Red and blue: increased and decreased expression, respectively. (D--F) Expression profiles of miRNAs. (D and E) In the volcano plots, purple, green, and black points represent miRNAs that were downregulated, upregulated, and not significantly different in APP/PS1 mice relative to wild-type control mice at 6 and 9 months, respectively. x axis: log2 ratio of miRNA expression levels between AD and wild-type. y axis: false discovery rate values (−log10 transformed) of miRNAs. (F) Cluster analysis of expression of miRNAs. Red and blue: increased and decreased expression, respectively. (G--I) Expression profiles of mRNAs. (G and H) In the volcano plots, purple, green, and black points represent mRNAs that were downregulated, upregulated, and not significantly different in APP/PS1 mice relative to wild-type control mice at 6 and 9 months, respectively. x axis: log2 ratio of mRNA expression levels between AD and wild-type. y axis: false discovery rate values (−log10 transformed) of mRNAs. (I) Cluster analysis of expression of mRNAs. Red and blue: increased and decreased expression, respectively.

qPCR Validation {#sec2.5}
---------------

To confirm the differential expression identified in our RNA-seq experiments, we used qPCR and analyzed 62 differentially expressed transcripts that were randomly selected: 26 circRNAs, 9 miRNAs, and 27 mRNAs. All selected transcripts were detected in the brain of 2- to 9-month-old APP/PS1 and wild-type mice, and exhibited statistically significant differential expression ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}). In summary, the qPCR results were highly consistent with the RNA-seq data.Figure 3Validation of circRNA Expression by Using qPCRThe identified differentially expressed transcripts (circRNAs, miRNAs, and mRNAs) were divided into three groups: 6yes9no, differential expression at 6 months, but not at 9 months; 6no9yes, no differential expression at 6 months but differential expression at 9 months; and 6yes9yes, differential expression at both 6 and 9 months. (A--C) 6yes9no group (A), 6no9yes group (B), and 6yes9yes group (C). circRNA expression was quantified relative to *Gapdh* expression level by using the comparative cycle threshold (ΔCT) method. Data are presented as means ± SD (n = 3; \*p \< 0.05, \*\*p \< 0.01).Figure 4Validation of miRNA Expression by Using qPCR(A--C) 6yes9no group (A), 6no9yes group (B), and 6yes9yes group (C). miRNA expression was quantified relative to *U6* expression level by using the comparative cycle threshold (ΔCT) method. Data are presented as means ± SD (n = 3; \*p \< 0.05, \*\*p \< 0.01).Figure 5Validation of mRNA Expression by Using qPCR(A--C) 6yes9no group (A), 6no9yes group (B), and 6yes9yes group (C). mRNA expression was quantified relative to *Gapdh* expression level by using the comparative cycle threshold (ΔCT) method. Data are presented as means ± SD (n = 3; \*p \< 0.05, \*\*p \< 0.01).

Construction of circRNA-Associated ceRNA Networks {#sec2.6}
-------------------------------------------------

According to the ceRNA hypothesis, RNA transcripts effectively communicate with one another, and ceRNAs can compete for the same miRNA response elements (MREs) in regulatory networks. Here, we used our RNA-seq data to identify, for the first time, ceRNA networks in the APP/PS1 brain. We divided the differentially expressed transcripts (circRNAs, miRNAs, and mRNAs) into three groups: (1) 6yes9no, differential expression at 6 months, but not at 9 months of age; (2) 6no9yes, no differential expression at 6 months but differential expression at 9 months; and (3) 6yes9yes, differential expression at both 6 and 9 months. The transcripts of the 6yes9no, 6no9yes, and 6yes9yes groups could, respectively, play roles in AD pathogenesis, participate in AD development, and contribute to the disease at all stages ([Figure 6](#fig6){ref-type="fig"}A).Figure 6circRNA-Associated ceRNA Networks in APP/PS1 MiceceRNA networks were constructed based on identified circRNA-miRNA and miRNA-mRNA interactions. The networks include increased circRNAs in APP/PS1 mice, decreased miRNAs in APP/PS1 mice, and increased mRNAs in APP/PS1 mice. (A--D) Grouping (A), 6yes9no group (B), 6no9yes group (C), and 6yes9yes group (D).

We selected 171 circRNAs and 1,104 mRNAs that were differentially expressed and shared common MRE binding sites (31 significantly dysregulated miRNAs) for inclusion in the 6yes9no group ([Tables S7](#mmc8){ref-type="supplementary-material"} and [S8](#mmc9){ref-type="supplementary-material"}). A total of 136, 1,078, and 47 significantly dysregulated circRNAs, mRNAs, and miRNAs, respectively, were included in the 6no9yes group ([Tables S9](#mmc10){ref-type="supplementary-material"} and [S10](#mmc11){ref-type="supplementary-material"}), and 3 circRNAs, 318 mRNAs, and 1 miRNA were included in the 6yes9yes group ([Table S11](#mmc12){ref-type="supplementary-material"}). The ceRNA networks included both positive and negative regulation ([Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}); [Figure 6](#fig6){ref-type="fig"} shows the circRNAs, miRNAs, and mRNAs that were increased, decreased, and increased in APP/PS1 mice, respectively, and [Figure 7](#fig7){ref-type="fig"} shows the circRNAs, miRNAs, and mRNAs that were decreased, increased, and decreased in APP/PS1 mice, respectively. These RNA interactions might be critical in AD pathogenesis.Figure 7circRNA-Associated ceRNA Networks in APP/PS1 MiceceRNA networks were constructed based on identified circRNA-miRNA and miRNA-mRNA interactions. The networks include decreased circRNAs in APP/PS1 mice, increased miRNAs in APP/PS1 mice, and decreased mRNAs in APP/PS1 mice. (A and B) 6yes9no group (A) and 6no9yes group (B).

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Pathway Analyses {#sec2.7}
--------------------------------------------------------------------------

A circRNA-associated ceRNA network can alter the regulation of the related mRNA-encoding genes. Gene Ontology (GO) analyses were performed on the genes in the networks identified here, and several GO terms were found to be significantly enriched ([Tables S12](#mmc13){ref-type="supplementary-material"}, [S13](#mmc14){ref-type="supplementary-material"}, and [S14](#mmc15){ref-type="supplementary-material"}). The top highly enriched GO terms of biological process (BP), cellular component (CC), and molecular function (MF) are shown in [Figure 8](#fig8){ref-type="fig"}. The top terms were cytoskeleton (GO: 0005856), postsynaptic density (GO: 0014069), cell-cell adherens junction (GO: 0005913), and dendrite (GO: 0030425). Several cognition-associated terms were also observed, such as axon (GO: 0030424), synapse (GO: 0045202), postsynaptic density (GO: 0014069), intracellular signal transduction (GO: 0035556), and neuron projection (GO: 0043005). The enriched GO terms for the 6yes9no group differed from those for the 6no9yes group, which suggests changes in the functional genes during disease progression. In summary, circRNA-associated ceRNA networks might participate in the pathological progression of AD at distinct stages and through different mechanisms. The functions of the key genes in AD can now be studied, and the regulatory mechanisms in the ceRNA network can be investigated.Figure 8Gene Ontology (GO) Enrichment Annotations of Pathological Progression of AD: Biological Process, Cellular Component, and Molecular FunctionThe top terms were synapse (GO: 0045202), cytoskeleton (GO: 0005856), postsynaptic density (GO: 0014069), cell-cell adherens junction (GO: 0005913), dendrite (GO: 0030425), axon (GO: 0030424), and neuron projection (GO: 0043005). (A--C) 6yes9no group (A), 6no9yes group (B), and 6yes9yes group (C). Significantly enriched GO pathways featured p values \<0.05. GO analysis was conducted using the DAVID (<https://david.ncifcrf.gov/summary.jsp>) database.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted to determine the signaling cascades related to the identified genes; by using p \< 0.05 as the threshold value, the following significantly enriched pathways were identified ([Figure 9](#fig9){ref-type="fig"}; [Tables S12](#mmc13){ref-type="supplementary-material"}, [S13](#mmc14){ref-type="supplementary-material"}, and [S14](#mmc15){ref-type="supplementary-material"}): neuroactive ligand-receptor interaction, AMP-activated protein kinase (AMPK) signaling, long-term potentiation, Hippo signaling, glutamatergic synapse, phosphatidylinositol 3-kinase (PI3K)-Akt signaling, insulin secretion, focal adhesion, and axon guidance.Figure 9Significantly Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome PathwayscircRNA-associated ceRNA network genes participate in distinct aspects of AD pathology. (A--C) 6yes9no group (A), 6no9yes group (B), and 6yes9yes group (C). Significantly enriched KEGG pathways featured p values \<0.05. Each line represents a gene, and the number of lines indicates the genes enriched. KEGG analysis was conducted using the DAVID (<https://david.ncifcrf.gov/summary.jsp>) database.

Association Study {#sec2.8}
-----------------

We selectively analyzed data in the case of circRNAs, miRNAs, and their target genes that showed significant differential expression between APP/PS1 and wild-type mice (corrected p \< 0.05); moreover, we used examples of the selected circRNAs, miRNAs, and their target genes that showed enrichment in the mouse brain to a certain order of magnitude, as well as those that were found to be associated with AD. We performed analyses under these conditions to investigate the most likely relationships between circRNA-associated ceRNA networks and AD. For example, mmu_circ_0000433, mmu_circ_0001473, novel_circ_0019965, novel_circ_0021924, novel_circ_0028455, novel_circ_0051361, and novel_circ_0058143 were identified as ceRNAs of mmu-miR-122b-3p, which targets *Cntnap2*. The expression of *Cntnap2* was higher in AD mice than in wild-type mice. *Cntnap2* influences the development of neural systems critical for learning and cross-modal integration, and disruption of this function could be associated with delayed learning.[@bib33]^,^[@bib34] Moreover, mmu_circ_0044900 was found to be a ceRNA of mmu-miR-449a-5p, mmu-miR-467a-3p, mmu-miR-540-3p, and mmu-miR-669f-3p, which target *Creb*. The p38-CREB-ICER molecules have been identified as key components of a negative-feedback mechanism necessary to regulate inflammation.[@bib35] The ceRNA mmu_circ_0044900 inhibits miRNA functions by acting as a sponge for miRNAs. Our analysis also revealed that miRNAs can act directly on target genes. For example, mmu-miR-219b-5p, mmu-miR-350-5p, mmu-miR-450b-5p, and mmu-miR-9b-5p target *Sorbs2*, which influences dendritic development and memory.[@bib36]^,^[@bib37] Additional results are listed in [Tables S7](#mmc8){ref-type="supplementary-material"}, [S8](#mmc9){ref-type="supplementary-material"}, [S9](#mmc10){ref-type="supplementary-material"}, [S10](#mmc11){ref-type="supplementary-material"}, and [S11](#mmc12){ref-type="supplementary-material"}. We predict that the identified circRNA-associated ceRNA networks are potentially involved in the regulation of AD.

Discussion {#sec3}
==========

AD is a fatal neurodegenerative disease that shows progressive development. Because of the complex pathogenesis of AD and the failure of drugs to cross the blood-brain barrier, effective diagnostic and therapeutic approaches for AD are lacking. Thus, several studies on AD have recently focused on the epigenetic regulation of AD pathogenesis to identify potential targets for therapy. For example, dynamic changes of DNA methylation and lncRNAs in the brain have been reported to contribute to AD.[@bib38]^,^[@bib39] However, the roles of circRNAs in AD have remained mostly unknown.

circRNAs lack 5′ caps and 3′ polyadenylated tails, and were therefore not detected in classical polyadenylated transcriptome studies. However, over the past few decades, the development of high-throughput sequencing and improved biochemical and computational biology methods have led to the identification of several circRNAs in various tissues and cells.[@bib40] These circRNAs have been implicated in myriad human diseases, including AD.[@bib18]^,^[@bib41] Furthermore, circRNAs have been used as diagnostic and prognostic biomarkers because of the high exonuclease-digestion resistance conferred by their covalently closed loop structure.[@bib42]^,^[@bib43] For example, CDR1as[@bib44] and circMTO1[@bib45], [@bib46], [@bib47] have been reported as key players in the regulation of pathophysiological processes, which makes them targets for clinical diagnosis and treatment. However, our identification of circRNAs here is incomplete, and the specific roles of circRNAs in AD are largely unknown.

To the best of our knowledge, this is the first comprehensive high-throughput sequencing analysis of circRNA, miRNA, and mRNA expression profiles in the APP/PS1 mouse model of AD. At threshold values here of fold-change ≥ 2.0 and p \< 0.05, dysregulated circRNAs, miRNAs, and mRNAs showed significant differential expression between AD and control groups. We consider these transcripts to be associated with the pathogenesis of AD. For instance, RTN4 interacts with BACE1 and inhibits its ability to produce Aβ[@bib48]; ALS2 plays a critical role in neuronal development and degeneration[@bib49]; and PDLIM5 is a homolog of AD-associated neuronal thread protein (AD7c-NTP), which is overexpressed in the early stage of AD, and overexpression of AD7c-NTP gene has been reported to cause neuritic sprouting and cell death.[@bib50] The miRNA mmu-miR-124 is involved in the transformation of neuronal progenitor or non-neuronal cells into neuron-like cells,[@bib51] and mmu-miR-134 regulates the development of cortical neurons.[@bib52] The miRNA mmu-miR-107 is markedly downregulated in the early stages of AD, and the miRNA binds to the 3′ UTR of *BACE1* and increases *BACE1* mRNA levels, which indicates that mmu-miR-107 regulates the progression of BACE1-accelerated disease.[@bib53] The level of mmu-miR-29 is also substantially reduced in AD patients, and mmu-miR-29 also regulates BACE1 expression.[@bib54]^,^[@bib55] Our qPCR validation study confirmed the profiles revealed by the high-throughput sequencing data, thus indicating the reliability of the sequencing data.

In this study, we used RNA-seq to systematically analyze circRNA, miRNA, and mRNA profiles in the brain of 6- and 9-month-old APP/PS1 mice. The transcripts of the 6yes9no group might play a crucial role in AD pathogenesis, and the stability and specific expression of these circRNAs could make them optimal biomarker candidates for AD; conversely, the transcripts in the 6no9yes group might function in AD development. Notably, transcripts in the 6yes9yes group are likely involved in the disease at all stages, and targeting these transcripts could facilitate the development of circRNA-based diagnostic tools and therapeutic strategies for AD. Overall, circRNA and miRNA molecules might act as key regulators of diverse aspects of AD. circRNAs and protein-coding mRNAs function as ceRNAs and super-sponges to regulate the expression of mRNA. Based on this theory, we obtained the miRNA-mRNA and miRNA-circRNA interaction data predicted by the tool miRanda and constructed a DEcircRNA-DEmiRNA-DEmRNA triple network for APP/PS1 and wild-type mouse brain. The selected circRNA-associated ceRNA networks could offer new insights into AD and thus suggest novel treatments for the disease.

We performed GO enrichment and KEGG analysis of the genes in the ceRNA networks and identified enriched terms that are relevant to the pathological process of AD, including synapse (GO: 0045202), cytoskeleton (GO: 0005856), postsynaptic density (GO: 0014069), cell-cell adherens junction (GO: 0005913), dendrite (GO: 0030425), axon (GO: 0030424), and neuron projection (GO: 0043005), as well as various pathways, including cAMP signaling, mitogen-activated protein kinase (MAPK) signaling, insulin secretion, Hippo signaling, adherens junction, focal adhesion, dopaminergic synapse, and PI3K-Akt signaling pathways. Analysis of the data revealed networks that participate in AD. One of these networks involves the gene *Scube2*. The ceRNAs mmu_circ_0000452, mmu_circ_0000453, novel_circ_0010838, novel_circ_0011428, novel_circ_0033961, and novel_circ_0037760 might bind to mmu-miR-466b-5p, which targets *Scube2*, a newly identified mammalian epidermal growth factor-related gene that plays a key role in mouse neural development and is critical for AD progression.[@bib56] The circRNA-associated ceRNA networks in AD are highly complicated and diverse. The APP/PS1 mouse model used in this study cannot represent the entire disease, which is mainly related to β-amyloid toxicity. Therefore, further investigation is required to understand the regulation of these networks in AD. In a recent study, circRNAs have been found to be associated with the pathogenesis in AD patients. The expression of circRNA might have strong predictive ability for human AD case status, indicating that the mechanism of circRNA in AD development needs to be further elucidated.[@bib57]

In conclusion, we elucidated the brain circRNA-associated ceRNA profiles of APP/PS1 and wild-type mice by using deep RNA-seq analysis. Our findings further expand the current knowledge regarding the biology of ceRNAs and their regulatory roles in AD pathogenesis. These newly identified networks reveal potential biomarkers or therapeutic targets for AD, and our results should serve as a valuable resource for the clinical diagnosis, treatment, and prevention of AD.

Materials and Methods {#sec4}
=====================

Tissue Preparation {#sec4.1}
------------------

Wild-type and APP/PS1 mice (originally from The Jackson Laboratory; strain name: "B6.Cg-Tg(APPswe, PSEN1dE9)85Dbo/Mmjax\[46\]") were purchased from the Model Animal Research Center of Nanjing University. The mice were housed one per cage under standard specific conditions (25°C, 50% humidity, 12/12-h light/dark cycle, and pathogen-free environment). The mice were provided free access to standard diet until they met age requirements (6 and 9 months); then three male mice were randomly selected from each group, and their cerebral cortex was collected for RNA-seq. All animal experiments were performed in accordance with animal use protocols approved by the Committee for the Ethics of Animal Experiments, Shenzhen Peking University--The Hong Kong University of Science and Technology Medical Center (SPHMC) (protocol number 2011-004).

RNA Extraction and Qualification {#sec4.2}
--------------------------------

Total RNA from each sample was isolated using TRIzol reagent (Invitrogen), according to the manufacturer's instructions, and then 1% agarose gels were used to monitor RNA degradation and contamination. RNA purity was assessed using a NanoPhotometer spectrophotometer (IMPLEN, CA, USA), RNA concentration was measured using a Qubit RNA Assay Kit in a Qubit 2.0 Fluorometer (Life Technologies, CA, USA), and RNA integrity was evaluated using the RNA Nano 6000 Assay Kit of a Bioanalyzer 2100 System (Agilent Technologies, CA, USA).

RNA-Seq {#sec4.3}
-------

Details of the mRNA-seq, miRNA-seq, and circRNA-seq methods are described in [Document S1](#mmc1){ref-type="supplementary-material"}.

Expression Analysis {#sec4.4}
-------------------

We calculated the FPKMs values of transcripts by using Cuffdiff (v.2.1.1) to evaluate the expression levels of protein-coding genes in each sample.[@bib58] The expression levels of miRNAs and circRNAs were estimated in terms of TPM values by following these criteria[@bib58]: transcripts featuring p values \<0.05 were regarded as being differentially expressed between APP/PS1 and wild-type mice: Normalized expression = (mapped reads)/(total reads) × 1,000,000.

ceRNA Network Analysis {#sec4.5}
----------------------

The expression levels of circRNAs, miRNAs, and mRNAs differed significantly between APP/PS1 and wild-type mice, and the RNAs were therefore further analyzed. We searched the sequences of the circRNAs and mRNAs to identify potential MREs. We used miRanda (<http://www.microrna.org/microrna/home.do>) to predict miRNA-binding seed-sequence sites, and an overlap of the same miRNA-binding sites on both circRNAs and mRNAs indicated potential circRNA-miRNA-mRNA interaction.

GO Annotations and KEGG Pathway Analyses {#sec4.6}
----------------------------------------

The DAVID (<https://david.ncifcrf.gov/summary.jsp>) database was used to analyze circRNA-miRNA-enriched genes. GO and KEGG terms featuring p values \<0.05 were considered significantly enriched.

circRNA-Associated ceRNA Network Construction {#sec4.7}
---------------------------------------------

circRNA-associated ceRNA networks were constructed and visually displayed using Cytoscape software v.3.5.0 (San Diego, CA, USA) based on the results obtained from analyzing high-throughput sequencing data, as described above. In the figures, distinct shapes and colors represent different RNA types, GO terms, and regulatory relationships.

Quantitative Real-Time PCR Validation {#sec4.8}
-------------------------------------

Total RNA was extracted using TRIzol reagent (Sigma) according to the manufacturer's protocol. RNA quantity was measured using a NanoDrop 2000 (Thermo Fisher Scientific). qRT-PCR was performed using the GoScript Reverse Transcription System (Promega) in a C1000 Thermal Cycler (Bio-Rad). The glyceraldehyde-3-phosphate dehydrogenase gene (*Gapdh*) was used as an internal control. Relative gene-expression levels were calculated using the 2^−ΔCT^ method.

Statistical Analysis {#sec4.9}
--------------------

Two normally distributed groups were compared using t tests. Parameters for the high-throughput sequencing-related data were calculated, and statistical computing was performed using R software. All data are expressed as means ± SD; p \< 0.05 was considered statistically significant.

Data Access {#sec4.10}
-----------

All raw and processed sequencing data generated in this study have been submitted to the NCBI GEO (<https://www.ncbi.nlm.nih.gov/geo/>) database under accession number GEO: [GSE132177](ncbi-geo:GSE132177){#intref0025}.
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